The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα - Wikidata - awgldk - TriplyDB

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

http://www.wikidata.org/entity/Q34287452

about

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Metastatic colonization by circulating tumour cells Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner New horizons in tumor microenvironment biology: challenges and opportunities BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.CLARITY and PACT-based imaging of adult zebrafish and mouse for whole-animal analysis of infections.Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma.Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.Three-dimensional bio-printing: A new frontier in oncology research.Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.Macrophages and therapeutic resistance in cancer.Current position of TNF-α in melanomagenesis.Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.Differentiation of THP1 Cells into Macrophages for Transwell Co-culture Assay with Melanoma Cells.Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.The role of myeloid cells in cancer therapies.Tumor Microenvironment and Differential Responses to Therapy.The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.Mechanisms of Drug Resistance in Melanoma.Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma.Genetically engineered mouse models of melanoma.Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.The impact of hypoxia on tumor-associated macrophages.The macrophage: Switches from a passenger to a driver during anticancer therapy.BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.Overcoming resistance to BRAF inhibitors.Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

P2860

Q26747247-7E6F5165-A931-49D2-A341-732502BCDA97 Q26796309-060C6DDD-6BF4-41DC-AB08-0A258F2F0F3D Q28076164-7C414D74-7C03-4791-A612-89E0F958AC82 Q30277902-5FA58B5C-A999-4CCA-915B-92DEDA1475E5 Q33769541-41CF5AAA-56B9-40EF-8B71-B4DE37C87DDF Q33902560-E82B7C89-FF80-4B04-BA91-E45D2DD6F985 Q35151324-E67F47C0-33C2-4EBC-B81E-160C530DA0D6 Q35251663-2CE0A479-7A97-43D0-BBAA-3F87F5927233 Q35738534-3F1C6101-2A29-4C31-98DE-EA2164F5905A Q36320144-BAD6243A-DF1E-4945-8600-613FC0AEFA6F Q36363028-2BF01E79-063E-4DC5-B51A-D8E84EA8D53D Q36395999-5FEA937F-B608-4B3A-B9A0-94906081AC7C Q36506537-75703733-0246-49B3-9801-47A42B499958 Q36821239-508F93EC-174B-45DA-A2DB-DA3CF3562DAC Q36882715-8386BE2F-7771-41E2-AAC9-5B298812FBBC Q37427668-9F2295B9-A8B3-4147-8689-B452DF14045B Q37618946-5C79FE4F-DD4B-4172-B48A-919055276735 Q37642457-7341701B-EF6D-447D-9BCF-2E8EC31CEDF9 Q38394400-187D7CA4-7FF2-4071-92AB-A8AC4DD93460 Q38413720-8980921B-9DD4-4714-AAD2-F11831695FCE Q38567932-C85E4AAB-7019-41AC-8959-3C07EEA6E5FD Q38753142-38B1D766-A751-4864-9471-36008CEBF2C7 Q38756275-A76C4B50-0F32-4098-B5E8-B31C47F0CD28 Q38781900-200BA8C6-5A49-4CED-BE0E-9632C8FF804F Q38842141-65A1845C-472D-498E-9956-1B85BE433812 Q38875474-EC56A4D7-C99D-44DC-9A06-43036D43A79E Q39141484-49482370-258C-4158-98C9-64EB37DD3782 Q39163758-533CEF7A-9BA0-4F2D-917E-F3B63CF865D6 Q39164873-7BCA1939-8FE0-4E36-9E34-412BC1C5D696 Q39169776-D25F2E2F-870D-4AFC-BE8F-80C9306EDF7D Q39181838-23999951-AC32-434D-921F-6728ADC65A9B Q39329577-5781E081-188D-4EE0-9DAF-9B48E583C0FE Q41198115-DC032127-90F1-4807-99C8-50DA2BECF44C Q41279859-E6C5AB8F-4779-485A-879B-36AF95EFAE41 Q41678839-6021DBFA-36D8-40AF-90E7-A5E042ACF7B2 Q41856338-61F043CB-C5F4-4A0D-AF56-BA5A122C98D6 Q42378351-F21DDB49-EA99-4C76-BBDE-9A59A47ED79E Q43298157-9433754A-1F34-4F58-8529-C515F4EDFD99 Q48090844-F8C35B62-C52F-48F6-9662-7F5C51FD0D40 Q48243258-1FE0DDB6-3051-4730-8A45-D59A6DCDF10A

P2860

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

http://www.wikidata.org/entity/Q34287452

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The immune microenvironment co ...... hrough macrophage-derived TNFα

@ast

The immune microenvironment co ...... hrough macrophage-derived TNFα

@en

The immune microenvironment co ...... hrough macrophage-derived TNFα

@nl

type

label

The immune microenvironment co ...... hrough macrophage-derived TNFα

@ast

The immune microenvironment co ...... hrough macrophage-derived TNFα

@en

The immune microenvironment co ...... hrough macrophage-derived TNFα

@nl

prefLabel

The immune microenvironment co ...... hrough macrophage-derived TNFα

@ast

The immune microenvironment co ...... hrough macrophage-derived TNFα

@en

The immune microenvironment co ...... hrough macrophage-derived TNFα

@nl

P1433

Q34287452-19AE2358-9644-4EE0-9411-B5B8AAD9E304

P1476

Q34287452-FC2F698D-3E44-48CE-BFA0-E7EBBC005811

P2093

Q34287452-594A344D-7007-4F25-AD66-D62E4B6B3B2E

Q34287452-88085E9D-88CA-4FC7-8DA0-B52AC6E7AF3D

Q34287452-BAE0F730-864F-4B2C-9EDC-546FC4678A93

Q34287452-C1C68F85-BF42-45DD-8B00-D010A73581B4

Q34287452-C6B7687A-99F5-4141-BC91-40B6CE284C2B

Q34287452-F7359379-94DA-41E1-8FA9-60324573AD64

Q34287452-FF379C3F-7AA9-4519-A70B-CFAAC514D817

P2860

Q34287452-0CAECF80-3234-4E50-9975-6A6DAE79B48D

Q34287452-0E475DEE-FB43-47AF-9590-B8F1ACC54186

Q34287452-0FC6E28D-67FA-41C1-BE88-C351AF47A48B

Q34287452-1CD9D4BA-3EC7-4F1D-962D-92AE311C58A9

Q34287452-1EFEEC9C-BC2F-4784-84E5-8F9D7BC42179

Q34287452-26A3139F-DF96-4306-9243-A420B2F85F43

Q34287452-328422BB-E2DD-4596-A3AE-ECA790D15DE2

Q34287452-3373890E-C180-4087-BA60-1C4E9F73F512

Q34287452-3475240B-6899-4197-808D-1D9B844C6FC7

Q34287452-3704E2E5-E5E5-4F69-8ACF-A8B11439921C

P304

Q34287452-E24F2EFC-BB27-4402-8598-E39B0C162D34

P31

Q34287452-4CAF2DF8-8340-4F66-9159-C57321718A96

P356

Q34287452-CF0D65A8-69F1-4809-A6BE-4AB549AA2CFF

P433

Q34287452-EFD8A982-54DB-4FFF-B50D-EC5DFA8C745D

P478

Q34287452-2BD5F296-9AE9-4956-B9A3-8AF72370F87A

P50

Q34287452-5EE036FA-F7EB-4198-B995-B2411D685AD6

Q34287452-789A49A8-BADE-4675-A6DA-B27D32F8E3A7

Q34287452-B0AE8EFA-ECFC-4748-BDF9-676B8D6F9E14

Q34287452-C7770CE3-9283-4075-8173-2833F79CF5DE

Q34287452-C9186488-7319-4C83-97F5-417E126B1336

Q34287452-E0EA6959-9948-48AF-AB61-45469D1154C1

P577

Q34287452-1883D9F3-64C7-4D81-A89F-08F4FE924E5B

P5875

Q34287452-91D4881E-6185-44C6-B2E6-6D75E4055B4B

P698

Q34287452-51DB66FD-1804-4A16-897A-F40AB1FADE7F

P921

Q34287452-3A66FD83-AD4E-4F5D-AB9E-9A054E739F92

P932

Q34287452-0EB12750-45F3-40AF-8B42-9C1AD551E0A0

P356

2159-8290.CD-13-1007

P1433

Cancer Discovery

P1476

The immune microenvironment co ...... hrough macrophage-derived TNFα

@en

P2093

Dennie T Frederick

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Jennifer Ferguson

http://www.w3.org/2001/XMLSchema#string

Kate O'Brien

http://www.w3.org/2001/XMLSchema#string

Keith T Flaherty

http://www.w3.org/2001/XMLSchema#string

Nathalie Dhomen

http://www.w3.org/2001/XMLSchema#string

Richard Marais

http://www.w3.org/2001/XMLSchema#string

P2860

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

MITF: master regulator of melanocyte development and melanoma oncogene

Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas

Hepatotoxicity with combination of vemurafenib and ipilimumab

Characterization of tumor necrosis factor-deficient mice

NF-kappaB: linking inflammation and immunity to cancer development and progression

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

P304

1214-1229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-1007

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Zachary A. Cooper

Michael P Smith

Berta Sanchez-Laorden

Claudia Wellbrock

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266243595

http://www.w3.org/2001/XMLSchema#string

P698

25256614

http://www.w3.org/2001/XMLSchema#string

P921

P932

4184867

http://www.w3.org/2001/XMLSchema#string